Chemo, radiation, and immunotherapy for rectal squamous cell carcinoma
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy (cisplatin and 5-FU), radiation, and an immunotherapy drug (PD-1 antibody) for people with a rare type of rectal cancer that hasn't spread. The goal is to see if this treatment can shrink or eliminate the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a specific type of rectal cancer called squamous cell carcinoma that has not spread to other parts of the body.
- You should not have had any previous treatment for this cancer, like surgery, chemotherapy, or radiation.
- You must be between 18 and 75 years old and in generally good health, with certain blood counts and liver/kidney function within normal limits.
- You should not have had another cancer in the past or serious heart or blood clot problems recently.
- You must be able to take part in the study and follow the instructions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining standard chemoradiation with an immunotherapy drug (toripalimab) before surgery for rectal cancer that has come back in the pelvis. The goal is to see if this approach can help remove the tumor more effectively.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial tests a treatment plan that uses a short course of radiation to the lymph nodes-sparing area, followed by chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of mid or low rectal cancer (pMMR/MSS). The goal is to see if this approach can shrink the tumor and improve outcomes without needing extensive surgery.
This trial tests whether adding a very low dose of radiation to a combination of immunotherapy (pucotenlimab) and chemotherapy (CAPEOX) can help shrink rectal cancer tumors that have not spread. It is for people with locally advanced rectal cancer that is pMMR (meaning the cancer cells have normal DNA repair).
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This trial tests whether combining chemotherapy, immunotherapy (PD-1 inhibitor), and a precise type of radiation can help shrink locally advanced rectal cancer before surgery. It aims to improve treatment success and reduce side effects.
Hear when a new Rectal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.